Understanding the critical disposition pathways of statins to assess drug–drug interaction risk during drug development: it's not just about OATP1B1

R Elsby, C Hilgendorf, K Fenner - Clinical Pharmacology & …, 2012 - Wiley Online Library
The use of statins is widespread across disease areas because many patients have
comorbidities. Given that these drugs have become common as comedications, it is …
被引用次数：222 相关文章

Understanding the Critical Disposition Pathways of Statins to Assess Drug-Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1.

R Elsby, C Hilgendorf, K Fenner - Clinical Pharmacology & …, 2012 - search.ebscohost.com
The use of statins is widespread across disease areas because many patients have
comorbidities. Given that these drugs have become common as comedications, it is …

Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.

R Elsby, C Hilgendorf, K Fenner - Clinical Pharmacology and …, 2012 - europepmc.org
The use of statins is widespread across disease areas because many patients have
comorbidities. Given that these drugs have become common as comedications, it is …

[引用][C] Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1

R Elsby, C Hilgendorf, K Fenner - Clinical Pharmacology & Therapeutics, 2012 - cir.nii.ac.jp
Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction
Risk During Drug Development: It's Not Just About OATP1B1 | CiNii Research CiNii 国立情報学 …

[引用][C] Understanding the Critical Disposition Pathways of Statins to Assess Drug―Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1

R ELSBY, C HILGENDORF… - Clinical pharmacology …, 2012 - pascal-francis.inist.fr
Understanding the Critical Disposition Pathways of Statins to Assess Drug―Drug Interaction Risk
During Drug Development: It's Not Just About OATP1B1 CNRS Inist Pascal-Francis CNRS …

Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1

R Elsby, C Hilgendorf, K Fenner - Clinical pharmacology …, 2012 - pubmed.ncbi.nlm.nih.gov
The use of statins is widespread across disease areas because many patients have
comorbidities. Given that these drugs have become common as comedications, it is …

[引用][C] Understanding the Critical Disposition Pathways of Statins to Assess Drug―Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1

R ELSBY, C HILGENDORF… - Clinical pharmacology …, 2012 - Nature Publishing Group